Principal Investigator
Eugene Schiff
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20221039
Clinical Trial Summary
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
NASH and compensated cirrhosis
Contact Information
Study Contact
Sonia Carvalho
Phone Number
+1 (305) 2434639
Email
scarvalho@miami.edu